N/A N=100 Femoral Central Venous Access Comparison of 2 Methods
Child
Primary: Installation on the First Try — 18; 42 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,203 A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)
Clostridium Difficile Infection
Primary: Percentage of Participants With CDI Recurrence — 14.9; 15.7; 25.7 Percentage of participants — p=<0.0001
Phase 3 N=32 Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Transplant; Failure, Kidney
Primary: BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant — 1; 3 participants — p=0.32
N/A N=61 Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis
Subacromial Bursitis · Shoulder Pain
Primary: Change in Shoulder Function, as Measured by the QuickDASH ® — 19.2; 21.3; 19.1; 24.7 units on a scale
N/A N=321 Effectiveness of Extended Treatments for Drug Dependence
Cocaine Dependence
Primary: Abstinence — 45; 57; 45 participants
Phase 2 N=13 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Thyroid Neoplasm
Primary: RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment — 6; 1; 1; 0 Participants
Phase 3 N=859 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea
Diabetes Mellitus, Type 2
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.10; -0.85 percentage of hemoglobin — p=<0.0001
N/A N=67 Acceptability of Less Harmful Alternatives to Cigarettes
Bladder Cancer · Cervical Cancer · Esophageal Cancer
Primary: Number of Participants With no Interest in Trial of Harm-reduction Products (HRPs) — 7 participants
N/A N=935 Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Osteoporosis, Age-Related
Primary: Percentage of Participants With Persistence With Prolia® at 12 Ponths — 87.8; 81.0 percentage of participants
Phase 2 N=21 Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer
Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Number of Participants With Partial and Complete Response. — 1 participant
Phase 2 N=10 Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism
Sialorrhea
Primary: Objectively Measured Salivary Weight — -0.07; -0.68 gm
Phase 3 N=484 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Diabetes Mellitus, Type 2
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.42; -0.83; -0.92 percentage of hemoglobin — p=<0.0001
Phase 3 N=268 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 83.3; 94.3; 87.8 percentage of participants…
N/A N=66 An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
Hemophilia A · Hemophilia B · Factor VIII Deficiency
Primary: MVPA — 48; 55 minutes per day — p=0.32
Phase 2 N=32 Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
Fallopian Tube Carcinoma · Primary Peritoneal Carcinoma · Recurrent Borderline Ovarian Surface Epithelial-Stromal Tumor
Primary: Efficacy of Belinostat in Terms of Complete or Partial Response; Disappearance of All Target Lesions or at Least a 30% Decrease in the Sum of the Longest Diameter of…